Viability by MRI or PET Would Have Changed the Results of the STICH Trial

Progress in Cardiovascular Diseases

Volumn 55, Issue 5, 2013, Pages 487-493

  Srichai, Monvadi B ^a   Jaber, Wael A ^b  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Cardiac MRI; Cardiac PET; Coronary artery disease; Dobutamine echocardiography; Ischemic heart disease; Myocardial viability

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; GADOLINIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THALLIUM;

ADULT; ARTICLE; CARDIAC IMAGING; CARDIOVASCULAR MAGNETIC RESONANCE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DIAGNOSTIC ACCURACY; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE REVASCULARIZATION; HUMAN; IMAGE PROCESSING; IMAGE QUALITY; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVASCULARIZATION; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTOLIC BLOOD PRESSURE;

AGED; CORONARY ARTERY BYPASS; EVALUATION STUDIES AS TOPIC; FEMALE; HEART FAILURE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; POSITRON-EMISSION TOMOGRAPHY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TISSUE SURVIVAL; TREATMENT OUTCOME; UNITED STATES;

EID: 84875249388     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2013.01.005     Document Type: Article

References (32)

1. Elefteriades J.A., Tolis G., Levi E., Mills L.K., Zaret B.L. Coronary artery bypass grafting in severe left ventricular dysfunction: excellent survival with improved ejection fraction and functional state. J Am Coll Cardiol 1993, 22:1411-1417.
2. Bax J.J., Poldermans D., Elhendy A., Boersma E., Rahimtoola S.H. Sensitivity, specificity, and predictive accuracies of various noninvasive techniques for detecting hibernating myocardium. Curr Probl Cardiol 2001, 26:147-186.
3. Chareonthaitawee P., Gersh B.J., Araoz P.A., Gibbons R.J. Revascularization in severe left ventricular dysfunction: the role of viability testing. J Am Coll Cardiol 2005, 46:567-574.
4. Allman K.C., Shaw L.J., Hachamovitch R., Udelson J.E. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002, 39:1151-1158.
5. Bourque J.M., Hasselblad V., Velazquez E.J., Borges-Neto S., O'Connor C.M. Revascularization in patients with coronary artery disease, left ventricular dysfunction, and viability: a meta-analysis. Am Heart J 2003, 146:621-627.
6. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005, 112:e154-e235.
7. Camici P.G., Prasad S.K., Rimoldi O.E. Stunning, hibernation, and assessment of myocardial viability. Circulation 2008, 117:103-114.
8. Fazel R., Krumholz H.M., Wang Y., et al. Exposure to low-dose ionizing radiation from medical imaging procedures. N Engl J Med 2009, 361:849-857.
9. Schinkel A.F., Bax J.J., Poldermans D., Elhendy A., Ferrari R., Rahimtoola S.H. Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol 2007, 32:375-410.
10. Pagano D., Bonser R.S., Townend J.N., Ordoubadi F., Lorenzoni R., Camici P.G. Predictive value of dobutamine echocardiography and positron emission tomography in identifying hibernating myocardium in patients with postischaemic heart failure. Heart 1998, 79:281-288.
11. Perrone-Filardi P., Pace L., Prastaro M., et al. Assessment of myocardial viability in patients with chronic coronary artery disease. Rest-4-hour-24-hour 201Tl tomography versus dobutamine echocardiography. Circulation 1996, 94:2712-2719.
12. Gerber B.L., Vanoverschelde J.L., Bol A., et al. Myocardial blood flow, glucose uptake, and recruitment of inotropic reserve in chronic left ventricular ischemic dysfunction. Implications for the pathophysiology of chronic myocardial hibernation. Circulation 1996, 94:651-659.
13. Romero J., Xue X., Gonzalez W., Garcia M.J. CMR imaging assessing viability in patients with chronic ventricular dysfunction due to coronary artery disease: a meta-analysis of prospective trials. JACC Cardiovasc Imaging 2012, 5:494-508.
14. Gerber B.L., Rousseau M.F., Ahn S.A., et al. Prognostic value of myocardial viability by delayed-enhanced magnetic resonance in patients with coronary artery disease and low ejection fraction: impact of revascularization therapy. J Am Coll Cardiol 2012, 59:825-835.
15. Beanlands R.S., Nichol G., Huszti E., et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol 2007, 50:2002-2012.
16. Velazquez E.J., Lee K.L., Deja M.A., et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 2011, 364:1607-1616.
17. Bonow R.O., Maurer G., Lee K.L., et al. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med 2011, 364:1617-1625.
18. Bax J.J., van der Wall E.E., Harbinson M. Radionuclide techniques for the assessment of myocardial viability and hibernation. Heart 2004, 90(Suppl. 5):v26-v33.
19. Oh J.K., Pellikka P.A., Panza J.A., et al. Core lab analysis of baseline echocardiographic studies in the STICH trial and recommendation for use of echocardiography in future clinical trials. J Am Soc Echocardiogr 2012, 25:327-336.
20. Cerqueira M.D., Weissman N.J., Dilsizian V., et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002, 105:539-542.
21. Pellikka P.A., Nagueh S.F., Elhendy A.A., Kuehl C.A., Sawada S.G. American Society of Echocardiography recommendations for performance, interpretation, and application of stress echocardiography. J Am Soc Echocardiogr 2007, 20:1021-1041.
22. Schiller N.B., Shah P.M., Crawford M., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989, 2:358-367.
23. Bax J.J., Maddahi J., Poldermans D., et al. Preoperative comparison of different noninvasive strategies for predicting improvement in left ventricular function after coronary artery bypass grafting. Am J Cardiol 2003, 92:1-4.
24. Cleland J.G., Pennell D.J., Ray S.G., et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet 2003, 362:14-21.
25. Bello D., Shah D.J., Farah G.M., et al. Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy. Circulation 2003, 108:1945-1953.
26. Kaandorp T.A., Bax J.J., Bleeker S.E., et al. Relation between regional and global systolic function in patients with ischemic cardiomyopathy after beta-blocker therapy or revascularization. J Cardiovasc Magn Reson 2010, 12:7.
27. Wu E., Ortiz J.T., Tejedor P., et al. Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index: prospective cohort study. Heart 2008, 94:730-736.
28. Kwong R.Y., Chan A.K., Brown K.A., et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation 2006, 113:2733-2743.
29. Kwon D.H., Halley C.M., Carrigan T.P., et al. Extent of left ventricular scar predicts outcomes in ischemic cardiomyopathy patients with significantly reduced systolic function: a delayed hyperenhancement cardiac magnetic resonance study. JACC Cardiovasc Imaging 2009, 2:34-44.
30. Kim H.W., Klem I., Shah D.J., et al. Unrecognized non-Q-wave myocardial infarction: prevalence and prognostic significance in patients with suspected coronary disease. PLoS Med 2009, 6:e1000057.
31. Catalano O., Moro G., Perotti M., et al. Late gadolinium enhancement by cardiovascular magnetic resonance is complementary to left ventricle ejection fraction in predicting prognosis of patients with stable coronary artery disease. J Cardiovasc Magn Reson 2012, 14:29.
32. Yoon Y.E., Kitagawa K., Kato S., et al. Prognostic significance of unrecognized myocardial infarction detected with MR imaging in patients with impaired fasting glucose compared with those with diabetes. Radiology 2012, 262:807-815.